



















# Mode of Action Classification



Insecticide Resistance Action Committee

## The Key to Resistance Management

- Successive generations of a pest should not be treated with compounds from the same MoA Group.
- Not all of the current groupings are based on knowledge of a shared target protein. For further information, please refer to the IRAC Mode of Action Classification document.
- The color scheme used here associates modes of action into broad categories based on the physiological functions affected, as an aid to understanding symptomology, speed of action and other properties of the insecticides, and not for any resistance management purpose. Rotations for resistance management should be based only on the numbered mode of action groups.



**Targeted Physiology**

- Nerve & Muscle
- Growth & Development
- Respiration
- Midgut
- Unknown or Non-specific

**Guidance on the use of Sub-Groups:**

- Represent distinct structural classes believed to have the same mode of action.
- Provide differentiation between compounds that may bind at the same target site but are structurally different enough that risk of metabolic cross-resistance is lower than for close chemical analogs.
- Cross-resistance potential between sub-groups is higher than between groups, so rotation between sub-groups should be considered only when there are no alternatives, and only if cross-resistance does not exist, following consultation with local expert advice. These exceptions are not sustainable, and alternative options should be sought.
- 3B: DDT is no longer used in agriculture and therefore this is only applicable for the control of human disease vectors such as mosquitoes, because of a lack of alternatives.

- 4A, 4B, 4C, 4D: Although these compounds are believed to have the same target site, current evidence indicates that the risk of metabolic cross-resistance between sub-groups is low.
- 10A - Hexythiazox is grouped with clofentezine because they exhibit cross-resistance even though they are structurally distinct, and the target site for these compounds is unknown. Diflovidazin has been added to this group because it is a close analogue of clofentezine and is expected to have the same mode of action.
- 22A & 22B - Although these compounds are believed to have the same target site, they have been sub-grouped because they are chemically distinct, and current evidence indicates that the risk of metabolic cross-resistance is low.
- Actives in groups 8 (Miscellaneous non-specific multi-site inhibitors), 13 (Uncouplers) and UN are thought not to share a common target site and therefore may be freely rotated with each other unless there is reason to expect cross-resistance.

**Poster Notes:**

- Groups 26 and 27 are unassigned.
- The poster is for educational purposes only. Information presented is accurate to the best of our knowledge at the time of publication, but IRAC or its member companies cannot accept responsibility for how this information is used or interpreted. Advice should always be sought from local experts or advisors, and health and safety recommendations followed.
- For further information visit the IRAC website: [www.irac-online.org](http://www.irac-online.org)